Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
Ex-Novartis Exec Unveils Neurodegeneration Gene Therapy Start-Up AviadoBio
AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.
GSK Poaches New Vaccines R&D Chief From Pfizer
Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.
GSK Looks To Long-Acting Therapy To Restore Lead In HIV
GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.
COVID-19 Vaccine Makers Pledge Rapid Response To Omicron Threat
While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.
Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
Gilead Trial Pause Adds To Merck & Co’s HIV Concerns
The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.